The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
News|Slideshows|April 10, 2026
AAD Issues First Pediatric Atopic Dermatitis Guidelines
Listen
0:00 / 0:00
The guidelines formalize a stepwise treatment approach ranging from emollients and topical steroids to systemic therapies.
Advertisement
References
- American Academy of Dermatology issues first-ever pediatric atopic dermatitis guidelines, highlighting prevention strategies and effective treatments. News release. American Academy of Dermatology. April 7, 2026. Accessed April 10, 2026.
https://www.aad.org/news/aad-issues-first-pediatric-atopic-dermatitis-guidelines - Davis DMER, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. JAAD. 2026. doi:10.1016/j.jaad.2026.02.113
- Gür Çetinkaya P, Şahiner ÜM. Childhood atopic dermatitis: current developments, treatment approaches, and future expectations. Turk J Med Sci. 2019;49(4):963-984. Published 2019 Aug 8. doi:10.3906/sag-1810-105
Advertisement
Related to this article
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Immunovant will discontinue development of imeroprubart in cutaneous lupus erythematosus after the phase 2b study failed to meet its primary endpoint.
This review of the latest dermatological studies includes insights on
Both barzolvolimab doses improved UAS7 at week 12 in EMBARQ-CSU1 and EMBARQ-CSU2, with up to 54% of patients reaching complete response by week 24.
The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.
Maui Derm NP+PA Fall 2026 brought APPs together for updates spanning inflammatory disease, oncology, emerging therapies, and diagnostic challenges.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Fast Track Designation to QRX003 for Peeling Skin Syndrome
2
Barzolvolimab Achieves All Phase 3 End Points in Chronic Spontaneous Urticaria
3
Don't Be Rash: Building the Pediatric Psoriasis Treatment Ladder
4
Alopecia Awareness Month: Supporting Patients Beyond the Treatment Plan
5